Haemonetics Corp income statement

In fiscal 2026, Haemonetics Corp reported revenue of $1.33bn, down 2.0% on the year before, operating income of $157m (a 11.7% margin) and net income of $97.3m, or $2.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Haemonetics Corp: income statement, annual
Fiscal year	2010Apr 2010	2011Apr 2011	2012Mar 2012	2013Mar 2013	2014Mar 2014	2015Mar 2015	2016Apr 2016	2017Apr 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Apr 2021	2022Apr 2022	2023Apr 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026	LTMJun 2026
Revenue	645	677	728	892	939	910	909	886	904	968	988	870	993	1,169	1,309	1,361	1,334	1,352
Cost of revenue	—	—	—	—	—	—	—	508	492	550	504	473	488	554	618	612	546	554
Gross profit	337	355	369	428	468	434	406	378	412	418	485	398	506	615	692	749	788	798
Research and development	26	33	37	44	54	54	45	38	39	36	31	33	47	50	54	63	60	60
Selling, general and administrative	214	214	244	323	366	337	317	302	317	273	282	275	340	377	430	437	442	451
Operating income	83	111	89	56	46	41	−44	−19	56	84	103	90	81	156	165	222	157	160
Interest expense	1	0	—	—	—	—	—	—	8	13	14	9	6	13	20	36	19	—
Income before tax	81	110	89	50	36	31	−53	−27	60	74	87	73	64	141	152	212	128	130
Income tax	23	30	23	11	1	14	2	−1	14	19	11	−7	20	26	34	44	31	34
Net income	58	80	67	39	35	17	−56	−26	46	55	77	79	43	115	118	168	97	96
Diluted EPS	$1.12	$1.56	$1.30	$0.74	$0.67	$0.32	−$1.09	−$0.51	$0.85	$1.04	$1.48	$1.55	$0.84	$2.24	$2.29	$3.31	$2.05	$2.06
Diluted shares (average)	52m	51m	52m	52m	52m	52m	51m	52m	54m	53m	52m	51m	51m	51m	51m	51m	47m	47m
EBITDA	127	159	139	122	128	127	46	70	145	193	214	174	178	249	262	337	268	270

US$ millions unless shown otherwise. Fiscal quarters.

Haemonetics Corp: income statement, quarterly
Quarter	2025 Q2Sept 2024	2025 Q3Dec 2024	2025 Q4Mar 2025	2026 Q1Jun 2025	2026 Q2Sept 2025	2026 Q3Dec 2025	2026 Q4Mar 2026	2027 Q1Jun 2026
Revenue	346	349	331	321	327	339	346	339
Cost of revenue	158	155	138	129	133	137	148	137
Gross profit	187	194	193	192	195	202	198	203
Research and development	14	16	18	16	15	14	14	16
Selling, general and administrative	107	106	115	111	102	109	121	119
Operating income	52	59	71	54	58	67	−23	57
Income before tax	45	50	71	45	51	60	−28	48
Income tax	11	12	13	11	13	15	−8	15
Net income	34	37	58	34	39	45	−20	33
Diluted EPS	$0.66	$0.74	$1.17	$0.70	$0.81	$0.95	−$0.41	$0.72
EBITDA	81	88	100	83	87	95	4	85

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HAE vs STVN HAE vs PEN HAE vs MMSI

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Haemonetics Corp's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Haemonetics Corp.